{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:49:23Z","timestamp":1791521363993,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Limited data exist on integrase strand transfer inhibitor (INSTI) use among children. We assessed dolutegravir (DTG) and raltegravir (RAL) use and outcomes among Latin American and Caribbean children with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Cohorts from Brazil, Haiti and Honduras contributed data for children (age &lt;18 years) receiving care since the widespread availability of DTG and RAL (approximately 2013\u20132022). Trends and factors associated with INSTI (DTG\/RAL) initiation were examined using multivariable logistic and Cox regression models among antiretroviral therapy (ART)-na\u00efve and -experienced children, respectively. We compared viral and treatment outcomes among ART-na\u00efve children by INSTI use with log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among ART-na\u00efve children, 77\/110 started DTG, 5\/109 started RAL and 91 started other ART. The proportion of ART-na\u00efve children initiating DTG increased from 0% in 2016 to 93% (13\/14) in 2022. Starting DTG was more likely in older ART-na\u00efve children and in more recent calendar years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.01). Among ART-experienced children, 122\/273 switched to DTG, and 25\/288 switched to RAL. More recent calendar year and a greater number of prior ART regimens were associated with a higher incidence of switch to DTG and RAL (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). There was no statistical difference in virologic suppression among ART-na\u00efve children by use or non-use of DTG; however, children started on DTG had a longer duration of the first regimen than those started on other ART (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>INSTI use among children has increased in parts of Latin American And Caribbean. As more children start INSTI regimens, further research is needed on their clinical impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005281","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:00:23Z","timestamp":1779422423000},"page":"979-985","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Use of Integrase Strand Transfer Inhibitors Among Children Living With HIV in Latin America and the Caribbean"],"prefix":"10.1097","volume":"45","author":[{"given":"Marco Tulio","family":"Luque","sequence":"first","affiliation":[{"name":"Departamento de Pediatria, Hospital Escuela, Tegucigalpa, Honduras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rouzier","sequence":"additional","affiliation":[{"name":"Haiti Department, Les Centres GHESKIO, Port-au-Prince, Haiti"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy M.","family":"Machado","sequence":"additional","affiliation":[{"name":"Paulista School of Medicine, Federal University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pinto","sequence":"additional","affiliation":[{"name":"School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan E.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7599-8173","authenticated-orcid":false,"given":"Jessica L.","family":"Castilho","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessse."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on Behalf of the Caribbean, Central and South America Network for HIV Epidemiology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"232","DOI":"10.15373\/22501991\/MAY2014\/73","article-title":"Global- HIV Statistics.","volume":"3","year":"2012","journal-title":"Paripex Indian J Res"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(11)70141-4","article-title":"HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.","volume":"11","author":"Sigaloff","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jia2.25267","article-title":"Pursuing use of optimal formulations for paediatric HIV epidemic control\u2014a look at the use of LPV\/r oral pellets and oral granules.","volume":"22","author":"Malati","year":"2019","journal-title":"J Intern AIDS Soc"},{"issue":"Suppl 6","key":"R5-20261009","first-page":"1","article-title":"Optimizing drugs to reach treatment targets for children and adolescents living with HIV.","volume":"18","author":"Penazzato","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jia2.25970","article-title":"Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.","volume":"25","author":"Townsend","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children.","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"108362","DOI":"10.1016\/j.ijid.2025.108362","article-title":"Protecting the promise of dolutegravir for children living with HIV.","volume":"163","author":"Mochankana","year":"2026","journal-title":"Int J Infect Dis"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2352-3018(22)00223-5","article-title":"The promise of paediatric dolutegravir in Zimbabwe.","volume":"9","author":"Makoni","year":"2022","journal-title":"Lancet HIV"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4102\/sajhivmed.v24i1.1506","article-title":"Paediatric antiretroviral update.","volume":"24","author":"Sorour","year":"2023","journal-title":"South Afr J HIV Med"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciad346","article-title":"Pharmacokinetic data of dolutegravir in second-line treatment of children with human immunodeficiency virus: results from the CHAPAS4 trial.","volume":"77","author":"Bevers","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(22)00044-3","article-title":"Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.","volume":"9","author":"Ruel","year":"2022","journal-title":"Lancet HIV"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ije\/dym073","article-title":"Cohort profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme.","volume":"36","author":"Mcgowan","year":"2007","journal-title":"Int J Epidemiol"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1097\/QAD.0000000000004007","article-title":"Transtion to dolutegravir-based ART in 35 low and middle income countries: a global survey of HIV care clinics.","volume":"38","author":"Zaniewski","year":"2024","journal-title":"AIDS"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAI.0000000000003065","article-title":"Brief report: virologic impact of the dolutegravir transition: prospective results from the multinational African cohort study.","volume":"91","author":"Allahna","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/INF.0000000000005118","article-title":"Low rates of virological failure and acquired HIV-1 drug resistance among children in cameroon: evidence following transition to dolutegravir-based regimens in pediatrics.","volume":"45","author":"Ndjolo Ada","year":"2026","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/QAI.0000000000003784","article-title":"Low levels of clinically significant drug resistance mutations to dolutegravir among children living with HIV failing on first-line antiretroviral therapy in Uganda.","volume":"101","author":"Magongo","year":"2026","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"105185","DOI":"10.1016\/j.idnow.2025.105185","article-title":"Efficacy of dolutegravir-based regimen in HIV-infected children in a treatment center in a regional health facility in Cameroon.","volume":"55","author":"Chiabi","year":"2025","journal-title":"Infect Dis Now"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/cid\/ciaf191","article-title":"Viral suppression, viral failure, and safety outcomes in children and adolescents with HIV on dolutegravir in Europe and Thailand.","volume":"81","author":"Scott","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/S2352-3018(24)00155-3","article-title":"Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.","volume":"12","author":"White","year":"2025","journal-title":"Lancet HIV"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3390\/biomedicines12092083","article-title":"Evaluation of viral suppression in paediatric populations: implications for the transition to dolutegravir-based regimens in cameroon: the CIPHER-ADOLA study.","volume":"12","author":"Fokam","year":"2024","journal-title":"Biomedicines"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M21-3037","article-title":"Disparities in dolutegravir uptake affecting females of reproductive age with HIV in low- and middle-income countries after initial concerns about teratogenicity: an observational study.","volume":"175","author":"Romo","year":"2022","journal-title":"Ann Intern Med"},{"key":"R28-20261009","article-title":"Disparities in access to Dolutegravir in West African children, adolescents and young adults aged 0-24 years living with HIV. A IeDEA Pediatric West African cohort analysis.","author":"Desmonde","year":"2024","journal-title":"medRxiv [Preprint]"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jia2.25580","article-title":"Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium.","volume":"23","author":"Patten","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/jac\/dkac259","article-title":"Integrase inhibitors in children and adolescents: clinical use and resistance.","volume":"77","author":"Torres-Fernandez","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/v16030399","article-title":"Prevalence of emergent dolutegravir resistance mutations in people living with HIV: a rapid scoping review.","volume":"16","author":"Chu","year":"2024","journal-title":"Viruses"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jia2.25961","article-title":"Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.","volume":"25","author":"Romo","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R33-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jia2.26174","article-title":"Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial.","volume":"26","author":"Barlow-Mosha","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"R34-20261009","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2352-4642(23)00164-5","article-title":"Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.","volume":"7","author":"Turkova","year":"2023","journal-title":"Lancet Child Adolesc Heal"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:02:47Z","timestamp":1791518567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005281","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2026-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}